Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depigmented polymerized Dermatophagoides pteronyssinus allergen extract
- Development stage
- Unknown
- Lead developer
- Leti Pharma
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
Depigmented polymerized Dermatophagoides pteronyssinus allergen extract, marketed under the brand name **Depigoid**, is an allergen immunotherapy (AIT) product developed by Laboratorios LETI. It is classified as an allergoid, a chemically modified allergen extract derived from the house dust mite *Dermatophagoides pteronyssinus*. The extract undergoes a proprietary European-patented process involving depigmentation (to remove non-allergenic components) and polymerization (using glutaraldehyde to cross-link proteins). This modification is designed to reduce the extract's allergenicity (IgE-binding capacity), thereby lowering the risk of systemic allergic reactions, while maintaining or enhancing its immunogenicity (T-cell reactivity). It is indicated for the treatment of house dust mite-induced allergic rhinitis and mite-allergic asthma, aiming to modify the natural course of the disease by inducing immunological tolerance.
- Brand names
- Depigoid
- Other names
- Depigmented polymerized D. pteronyssinus extractD. pteronyssinus allergoidDepigoid Dermatophagoides pteronyssinus
02
Targets
pMHCII-TCR (Allergen-specific T-cell receptors / peptide-MHC class II immune recognition pathway)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)Dermatophagoides pteronyssinus allergen epitopes
Beyond the preview
Go deeper on depigmented polymerized Dermatophagoides pteronyssinus allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depigmented polymerized Dermatophagoides pteronyssinus allergen extract.